Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change

Can-Fite BioPharma (CANF) announced that following the approval of its shareholders, its board of directors has approved a 1-for-3,000 reverse split of the company’s ordinary shares. The reverse split will be recorded with the Tel-Aviv Stock Exchange on January 2, 2026 and on January 4, 2026, the Tel-Aviv Stock Exchange will be closed. The first trading date for the newly consolidated ordinary shares on the Tel-Aviv Stock Exchange will be January 5, 2026. Concurrently with the reverse split, the company will effect a corresponding change in the ratio of ordinary shares underlying each of the company’s American Depositary Shares, such that its ratio of ADSs to ordinary shares will change from one ADS representing three hundred (300) ordinary shares to a new ratio of one ADS representing two ordinary shares and no adjustment will be made to the outstanding number of the ADSs of the company. The ratio change will be effective on the NYSE American on January 5, 2026.